But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals ...

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

Being first to market with a drug can be crucial. Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved in its home country ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

Some drugs initially approved to treat Type 2 diabetes are now being used for cosmetic weight loss. WSJ’s Daniela Hernandez ... to hitting the market. Eli Lilly said its experimental pill ...

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk (NYSE: NVO )’s Wegovy across five ...

April 17 (UPI) --People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug ... U.S. Food and Drug Administration on Friday approved three new ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug ... never been approved by the FDA. "Fella even tells patients that its untested oral drug is better than Lilly's approved ...

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages ... is a once-daily pill that, if approved, could be "readily ...

Lilly is confident that if orforglipron is approved it will be able to launch ... shouldn’t be used to directly assess the drug’s weight-loss potential. “Based on prior studies of ...